02.12.2014 Views

Innovation in European healthcare – what can Sweden learn? - LIF

Innovation in European healthcare – what can Sweden learn? - LIF

Innovation in European healthcare – what can Sweden learn? - LIF

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

The implementation of NICE guidel<strong>in</strong>es is mandatory and<br />

expected to be carried out through all NHS trusts with<strong>in</strong> three<br />

months<br />

• However, studies have shown considerable geographical variation <strong>in</strong> uptake of NICE<br />

guidance, suggest<strong>in</strong>g a persistence of the former ‘post-code lottery system’ of ration<strong>in</strong>g<br />

<strong>healthcare</strong>.<br />

– Implement<strong>in</strong>g NICE technology guidance with<strong>in</strong> three months is supported by fund<strong>in</strong>g for PCTs based on estimated<br />

costs.<br />

– However high capital costs, implementations of expensive drugs or prostheses, and compet<strong>in</strong>g local priorities, have<br />

dis<strong>in</strong>centivised PCTs from fund<strong>in</strong>g expensive guidance from their allocations.<br />

– The estimated cumulative total cost of implement<strong>in</strong>g NICE guidance between 1999-2004 was £800 million, which at<br />

that time, represented a total of 1% of NHS expenditure.<br />

• A study by the UK National Audit Commission <strong>in</strong>dicated that improv<strong>in</strong>g the implementation of<br />

NICE guidance is more likely with the follow<strong>in</strong>g motivations:<br />

– Established systems of track<strong>in</strong>g implementation: A system must be <strong>in</strong>clusive of professionals <strong>in</strong>volved <strong>in</strong><br />

implementation to motivate them and hold them accountable.<br />

– Weaknesses <strong>in</strong> f<strong>in</strong>ancial management: Costs of implementation are generally unknown when budgets are set at<br />

a local level because of 1) lack of knowledge of current and future guidance, 2) uncerta<strong>in</strong>ty of the full costs. Fund<strong>in</strong>g<br />

as historically only <strong>in</strong>cluded the actual costs of the drug/technology appraised, not the associated costs of staff<strong>in</strong>g,<br />

tra<strong>in</strong><strong>in</strong>g and equipment.<br />

– Cl<strong>in</strong>ical resistance: Perceived as a bigger challenge than fund<strong>in</strong>g restrictions. An enthusiastic champion (usually a<br />

cl<strong>in</strong>ician) who develops a strong bus<strong>in</strong>ess case as part of their local delivery plan is more likely to secure the funds<br />

needed.<br />

183

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!